News and Events

The HIV care landscape is constantly evolving, with breakthroughs in the methods, strategies and treatments to control and prevent transmission. This section aims to provide timely news updates and clinically relevant information about HIV disease management to clinicians who are actively involved in HIV care.

Upcoming events such as conferences, online seminars and continuing education programs will be listed here on a regular basis.

1st October 2018

Guideline recommendations

Key recommendations from the latest EACS and DHHS guidelines for GENVOYA®▼ (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide) are listed below, with links to the full publications.

1st October 2018

Key facts

Please click on the tabs below to find recommendations on how to prescribe GENVOYA®▼(elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide). Full details can be found in the GENVOYA® Summary of Product Characteristics.

1st October 2018

Safety and tolerability

The safety data for GENVOYA®▼ (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide) is based on data from all phase 2 and 3 studies, involving 2,396 HIV-positive individuals.1

1st October 2018

Efficacy and resistance

The regulatory approval of GENVOYA®▼ (elvitegravir / cobicistat / emtricitabine /
tenofovir alafenamide)
is based on the results from six phase 2/3 studies in various HIV-positive populations: treatment-naïve adults, virologically suppressed adults, and adults with renal impairment and children.1

28th September 2018


GENVOYA® is a once-daily single-tablet regimen1 containing:

  • emtricitabine (FTC) and tenofovir alafenamide fumarate (TAF); two nucleoside reverse transcriptase inhibitors (NRTIs), and
  • elvitegravir (EVG), an integrase strand transfer inhibitor (INSTI), boosted with cobicistat (c).